Characterization of Infections with Vancomycin-Intermediate Staphylococcus aureus (VISA) and Staphylococcus aureus with Reduced Vancomycin Susceptibility in South Korea

被引:0
|
作者
Jung Wan Park
Hyungmin Lee
Jung Wook Kim
Bongyoung Kim
机构
[1] Korea Centers for Disease Control and Prevention,Department of Healthcare
[2] Asan Medical Center,Associated Infection Control
[3] University of Ulsan College of Medicine,Department of Infectious Diseases
[4] Center for Infectious Diseases Research,Division of Antimicrobial Resistance
[5] Korea National Institute of Health,Department of Internal Medicine
[6] Korea Centers for Disease Control and Prevention,undefined
[7] Hanyang University College of Medicine,undefined
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
The aim of the present study was to describe the characteristics of infections with Staphylococcus aureus with reduced vancomycin susceptibility (SARVS) including vancomycin-intermediate S. aureus (VISA) in South Korea, using data from the national sentinel surveillance system during 2014–2016. A total of 66 patients infected or colonized with SA-RVS were reported using the sentinel surveillance system. Among them, VISA was confirmed in 14 isolates (21.2%) and no vancomycin-resistant S. aureus (VRSA) was detected. Most of patients had any kind of indwelling devices (81.8%, 54/66) and underwent surgical procedures in the previous 6 months (84.8%, 56/66). Patients who admitted to an intensive care unit (ICU) in the previous 3 months were 68.2% (45/66). Furthermore, patients who used vancomycin or had MRSA in the previous 1 month were 54.5% (36/66) and 59.1% (39/66), respectively. Upon review of the medical records, 54.5% (36/66) of patients were classified as having SA-RVSassociated infection and 30-day mortality was 19.4% (7/36). Our findings revealed that there was no VRSA in South Korea. SA-RVS including VISA existed particularly in patients who had indwelling devices, history of surgical procedure, and history of ICU admission.
引用
收藏
相关论文
共 50 条
  • [41] Generation of a vancomycin-intermediate Staphylococcus aureus (VISA) strain by two amino acid exchanges in VraS
    Berscheid, Anne
    Francois, Patrice
    Strittmatter, Axel
    Gottschalk, Gerhard
    Schrenzel, Jacques
    Sass, Peter
    Bierbaum, Gabriele
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2014, 69 (12) : 3190 - 3198
  • [42] Occurrence of a USA300 vancomycin-intermediate Staphylococcus aureus
    Hageman, Jeffrey C.
    Patel, Jean
    Franklin, Patrick
    Miscavish, Karen
    McDougal, Linda
    Lonsway, David
    Khan, Fazle N.
    DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2008, 62 (04) : 440 - 442
  • [43] Molecular epidemiology of heteroresistant vancomycin-intermediate Staphylococcus aureus in Brazil
    de Oliveira Silveira, Alessandro Conrado
    da Cunha, Gabriela Rosa
    Caierao, Juliana
    Mendes de Cordova, Caio Mauricio
    d'Azevedo, Pedro Alves
    BRAZILIAN JOURNAL OF INFECTIOUS DISEASES, 2015, 19 (05): : 466 - 472
  • [44] Survivability and fitness cost of heterogeneous vancomycin-intermediate Staphylococcus aureus
    Singh, Avinash
    Singh, Sanjay
    Singh, Jyoti
    Rahman, Mohibur
    Pathak, Ashutosh
    Prasad, Kashi Nath
    INDIAN JOURNAL OF MEDICAL MICROBIOLOGY, 2017, 35 (03) : 415 - 416
  • [45] Emergence of vancomycin-intermediate resistant Staphylococcus aureus in north of Palestine
    Ghaleb Adwan
    Bassam Abu-Shanab
    Marwan Odeh
    Asian Pacific Journal of Tropical Medicine, 2009, 2 (05) : 44 - 48
  • [46] Exposure of Staphylococcus aureus to Subinhibitory Concentrations of β-Lactam Antibiotics Induces Heterogeneous Vancomycin-Intermediate Staphylococcus aureus
    Roch, Melanie
    Clair, Perrine
    Renzoni, Adriana
    Reverdy, Marie-Elisabeth
    Dauwalder, Olivier
    Bes, Michele
    Martra, Annie
    Freydiere, Anne-Marie
    Laurent, Frederic
    Reix, Philippe
    Dumitrescu, Oana
    Vandenesch, Francois
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2014, 58 (09) : 5306 - 5314
  • [47] Resistance and Molecular Characteristics of Methicillin-Resistant Staphylococcus aureus and Heterogeneous Vancomycin-Intermediate Staphylococcus aureus
    Liang, Jin
    Hu, Yuanfang
    Fu, Mingxia
    Li, Na
    Wang, Fengxia
    Yu, Xiaojun
    Ji, Bing
    INFECTION AND DRUG RESISTANCE, 2023, 16 : 379 - 388
  • [48] Genetic analysis of 17 genes in Staphylococcus aureus with reduced susceptibility to vancomycin (VISA) and heteroVISA
    Wootton, M
    Avison, MB
    Bennett, PM
    Howe, RA
    MacGowan, AP
    Walsh, TR
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2004, 53 (02) : 406 - 407
  • [49] Relationship between Vancomycin-Resistant Staphylococcus aureus, Vancomycin-Intermediate S. aureus, High Vancomycin MIC, and Outcome in Serious S. aureus Infections
    Holmes, Natasha E.
    Johnson, Paul D. R.
    Howden, Benjamin P.
    JOURNAL OF CLINICAL MICROBIOLOGY, 2012, 50 (08) : 2548 - 2552
  • [50] Contribution of vraSR and graSR Point Mutations to Vancomycin Resistance in Vancomycin-Intermediate Staphylococcus aureus
    Cui, Longzhu
    Neoh, Hui-min
    Shoji, Mitsutaka
    Hiramatsu, Keiichi
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (03) : 1231 - 1234